Market Closed -
Nasdaq
04:00:00 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
4.95
USD
|
+5.77%
|
|
+3.99%
|
-26.88%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,731
|
1,316
|
843
|
991.7
|
293.3
|
221.6
|
-
|
-
|
Enterprise Value (EV)
1 |
2,425
|
1,143
|
438.9
|
873.5
|
180.7
|
152.2
|
230.6
|
-63.39
|
P/E ratio
|
-22.9
x
|
-12.7
x
|
2.92
x
|
-8.25
x
|
-1.03
x
|
-1.07
x
|
-1.35
x
|
-1.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
418
x
|
42.5
x
|
1.81
x
|
9.83
x
|
20.1
x
|
4.48
x
|
2.53
x
|
1.84
x
|
EV / Revenue
|
371
x
|
36.9
x
|
0.94
x
|
8.65
x
|
12.4
x
|
3.08
x
|
2.63
x
|
-0.53
x
|
EV / EBITDA
|
-23.6
x
|
-12
x
|
1.56
x
|
-6.85
x
|
-0.72
x
|
-1
x
|
-1.87
x
|
0.71
x
|
EV / FCF
|
-25.9
x
|
-9.7
x
|
1.83
x
|
-5.69
x
|
-1.28
x
|
-0.84
x
|
-1.85
x
|
0.64
x
|
FCF Yield
|
-3.86%
|
-10.3%
|
54.7%
|
-17.6%
|
-78.2%
|
-119%
|
-54.1%
|
156%
|
Price to Book
|
8.82
x
|
6.5
x
|
1.6
x
|
2.21
x
|
1.53
x
|
5.14
x
|
-3.26
x
|
-
|
Nbr of stocks (in thousands)
|
42,731
|
44,496
|
46,214
|
46,815
|
47,810
|
48,549
|
-
|
-
|
Reference price
2 |
63.92
|
29.58
|
18.24
|
21.18
|
6.134
|
4.564
|
4.564
|
4.564
|
Announcement Date
|
3/2/20
|
3/1/21
|
2/25/22
|
2/27/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
6.531
|
31.01
|
465.1
|
100.9
|
14.6
|
49.47
|
87.7
|
120.5
|
EBITDA
1 |
-102.7
|
-95.19
|
282.2
|
-127.6
|
-249.7
|
-152.7
|
-123.4
|
-89.55
|
EBIT
1 |
-108.7
|
-103.7
|
275.7
|
-135.7
|
-260.7
|
-177.6
|
-138
|
-133.8
|
Operating Margin
|
-1,663.78%
|
-334.34%
|
59.28%
|
-134.44%
|
-1,785.46%
|
-359.09%
|
-157.36%
|
-110.99%
|
Earnings before Tax (EBT)
1 |
-111.4
|
-117.3
|
295.4
|
-121.6
|
-282.5
|
-224
|
-174
|
-162.7
|
Net income
1 |
-111.4
|
-103.7
|
292.5
|
-120.2
|
-284.3
|
-217.9
|
-167.3
|
-157
|
Net margin
|
-1,705.82%
|
-334.4%
|
62.9%
|
-119.07%
|
-1,947.09%
|
-440.55%
|
-190.73%
|
-130.26%
|
EPS
2 |
-2.790
|
-2.322
|
6.249
|
-2.569
|
-5.962
|
-4.260
|
-3.374
|
-2.856
|
Free Cash Flow
1 |
-93.59
|
-117.8
|
240.1
|
-153.6
|
-141.3
|
-181.2
|
-124.7
|
-99
|
FCF margin
|
-1,432.98%
|
-380.07%
|
51.63%
|
-152.21%
|
-967.82%
|
-366.25%
|
-142.23%
|
-82.13%
|
FCF Conversion (EBITDA)
|
-
|
-
|
85.09%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
82.08%
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/2/20
|
3/1/21
|
2/25/22
|
2/27/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
51.21
|
1.7
|
0.4894
|
1.468
|
97.38
|
4.833
|
2.198
|
1.317
|
6.164
|
7.872
|
6.254
|
6.057
|
33.43
|
12.71
|
13.63
|
EBITDA
1 |
3.479
|
-49.45
|
-52.92
|
-58.21
|
27.33
|
-65.39
|
-56.99
|
-74.18
|
-53.04
|
-
|
-48.06
|
-49.54
|
-51.02
|
-
|
-
|
EBIT
1 |
1.836
|
-51.32
|
-55.2
|
-60.3
|
25.12
|
-67.32
|
-59.05
|
-76.23
|
-56.9
|
-50.31
|
-47.76
|
-48.1
|
-26.8
|
-33.91
|
-34.3
|
Operating Margin
|
3.58%
|
-3,017.85%
|
-11,279.79%
|
-4,107.53%
|
25.79%
|
-1,392.9%
|
-2,686.79%
|
-5,790.03%
|
-923.13%
|
-639.1%
|
-763.62%
|
-794.09%
|
-80.17%
|
-266.8%
|
-251.61%
|
Earnings before Tax (EBT)
1 |
6.981
|
-44.88
|
-38.77
|
-48.82
|
6.255
|
-71.19
|
-61.99
|
-83.45
|
-64.66
|
-60.27
|
-52.7
|
-53.1
|
-49.42
|
-34.66
|
-35.21
|
Net income
1 |
7.285
|
-44.29
|
-38.46
|
-48.48
|
6.452
|
-70.09
|
-62.13
|
-83.39
|
-67.46
|
-60.87
|
-53.76
|
-54.55
|
-40.36
|
-34.66
|
-35.21
|
Net margin
|
14.23%
|
-2,604.8%
|
-7,859.29%
|
-3,302.77%
|
6.63%
|
-1,450.27%
|
-2,827.17%
|
-6,334.12%
|
-1,094.42%
|
-773.34%
|
-859.68%
|
-900.67%
|
-120.76%
|
-272.7%
|
-258.34%
|
EPS
2 |
0.1509
|
-0.9489
|
-0.8271
|
-1.033
|
0.1422
|
-1.479
|
-1.307
|
-1.750
|
-1.410
|
-1.262
|
-1.123
|
-1.132
|
-0.8994
|
-0.9207
|
-0.9245
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/25/22
|
5/2/22
|
8/8/22
|
11/2/22
|
2/27/23
|
5/9/23
|
8/1/23
|
11/7/23
|
2/28/24
|
5/7/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
9.03
|
-
|
Net Cash position
1 |
307
|
174
|
404
|
118
|
113
|
69.4
|
-
|
285
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-0.0732
x
|
-
|
Free Cash Flow
1 |
-93.6
|
-118
|
240
|
-154
|
-141
|
-181
|
-125
|
-99
|
ROE (net income / shareholders' equity)
|
-49.4%
|
-44.1%
|
78.5%
|
-23.7%
|
-90.2%
|
-144%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-34.4%
|
-31.7%
|
57.3%
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
324.1
|
327.2
|
510.2
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
7.240
|
4.550
|
11.40
|
9.570
|
4.010
|
0.8900
|
-1.400
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
5.07
|
6.03
|
15.5
|
16.7
|
6.6
|
6.96
|
5.75
|
6.86
|
Capex / Sales
|
77.61%
|
19.45%
|
3.33%
|
16.54%
|
45.23%
|
14.07%
|
6.55%
|
5.69%
|
Announcement Date
|
3/2/20
|
3/1/21
|
2/25/22
|
2/27/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
4.564
EUR Average target price
17.09
EUR Spread / Average Target +274.40% Consensus |
1st Jan change
|
Capi.
|
---|
| -26.88% | 240M | | +11.91% | 118B | | +11.60% | 106B | | -4.68% | 24.28B | | -0.82% | 21.96B | | -10.12% | 18.16B | | -42.12% | 16.37B | | -17.47% | 15.56B | | +2.77% | 13.63B | | +34.58% | 12.27B |
Bio Therapeutic Drugs
|